Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18981054 | ANTI-HUMAN NR1 ANTIBODY DERIVATIVE | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18899511 | METHOD FOR AMELIORATING OR AVOIDING THE ADVERSE EFFECTS OF EXOGENOUS GONADOTROPINS ON REPRODUCTIVE PERFORMANCE | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18892253 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING PTK7 | September 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18823422 | ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOF | September 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18738824 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | June 2024 | March 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18731146 | HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF | May 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18631672 | ANTIBODIES BINDING PD-1 AND USES THEREOF | April 2024 | March 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18630179 | CONJUGATES COMPRISING CLEAVABLE BETA-GLUCURONIDE-CONTAINING LINKERS | April 2024 | December 2024 | Allow | 8 | 1 | 1 | No | No |
| 18609223 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18609247 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18604668 | ANTIBODIES TO AMYLOID BETA | March 2024 | February 2025 | Allow | 11 | 0 | 0 | No | No |
| 18603613 | BARCODE DIFFUSION-BASED SPATIAL OMICS | March 2024 | May 2024 | Allow | 2 | 0 | 0 | No | No |
| 18600801 | COMPOSITIONS AND METHODS FOR DISSOLVING PROTEIN AGGREGATES | March 2024 | June 2025 | Allow | 15 | 2 | 0 | No | No |
| 18592478 | RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION FOR THE TREATMENT OF CORNEAL ENDOTHELIAL DYSFUNCTION | February 2024 | January 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18443769 | GDNF FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18435815 | HUMAN ANTIBODIES TO ARTEMIN AND METHODS OF USE THEREOF | February 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18435766 | METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | February 2024 | August 2024 | Abandon | 6 | 1 | 1 | No | No |
| 18435809 | ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF | February 2024 | March 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18430862 | COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR | February 2024 | May 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18430589 | FUSION IMAGING GENE AND LENTIVIRAL EXPRESSION PLASMID, LENTIVIRUS, CELL, PREPARATION METHODS AND APPLICATIONS THEREOF | February 2024 | August 2024 | Allow | 7 | 0 | 1 | No | No |
| 18416639 | SYSTEMS AND METHODS FOR BIOMOLECULE RETENTION | January 2024 | May 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18415419 | HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF | January 2024 | December 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18400744 | IMMUNE PROFILING BY PRIMER EXTENSION TARGET ENRICHMENT | December 2023 | April 2024 | Allow | 3 | 1 | 0 | No | No |
| 18395097 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING COX2 ACETYLATING AGENT AS ACTIVE INGREDIENT | December 2023 | June 2025 | Allow | 18 | 2 | 0 | No | No |
| 18540403 | Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s) | December 2023 | February 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18537578 | METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18536654 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18533066 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | December 2023 | April 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18529590 | METHODS FOR PROMOTING WOUND HEALINGAND HAIR GROWTH COMPRISING GDNF ADMINISTRATION | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18526952 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES | December 2023 | June 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18524769 | SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAME | November 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18525736 | NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOF | November 2023 | September 2024 | Allow | 10 | 1 | 1 | No | No |
| 18386066 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES FROM INDIVIDUAL CELLS OR CELL POPULATIONS | November 2023 | May 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18494355 | IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF | October 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18493744 | ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN | October 2023 | July 2025 | Abandon | 20 | 1 | 0 | Yes | No |
| 18492028 | ENGINEERED ANTI-IL-2 ANTIBODIES | October 2023 | December 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18489216 | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18478846 | Antibody Molecules to C5AR1 and Uses Thereof | September 2023 | May 2025 | Allow | 19 | 1 | 1 | No | No |
| 18475838 | COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY | September 2023 | August 2024 | Allow | 11 | 2 | 0 | No | No |
| 18372072 | DIMERIZATION SCREENING ASSAYS | September 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18472920 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | September 2023 | April 2025 | Allow | 18 | 1 | 1 | No | No |
| 18471948 | PROFILING OF BIOLOGICAL ANALYTES WITH SPATIALLY BARCODED OLIGONUCLEOTIDE ARRAYS | September 2023 | October 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18466722 | ILT-BINDING AGENTS AND METHODS OF USE THEREOF | September 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18243915 | SENSE INDICATOR COMPOSITION | September 2023 | March 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18462936 | METHODS OF DETECTING ANALYTES | September 2023 | September 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18243457 | METHODS OF DETECTING ANALYTES | September 2023 | July 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18306992 | ERYTHROCYTE-DERIVED EXTRACELLULAR VESICLES AND PROTEINS ASSOCIATED WITH SUCH VESICLES AS BIOMARKERS FOR PARKINSON'S DISEASE | September 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18455683 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | August 2023 | April 2025 | Allow | 20 | 0 | 0 | No | No |
| 18455181 | ANTI-CD200R1 ANTIBODIES AND METHODS OF USE THEREOF | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18453286 | BIOMARKERS AND METHODS OF USE FOR RADIATION-INDUCED LUNG INJURY | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18452173 | Antibody Molecules to C5AR1 and Uses Thereof | August 2023 | August 2024 | Allow | 12 | 0 | 1 | No | No |
| 18451884 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | August 2023 | May 2025 | Allow | 21 | 0 | 0 | No | No |
| 18451883 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | August 2023 | March 2025 | Allow | 19 | 0 | 0 | No | No |
| 18449971 | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18448260 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | August 2023 | March 2025 | Allow | 19 | 0 | 0 | No | No |
| 18448725 | METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES | August 2023 | December 2023 | Allow | 4 | 1 | 0 | No | No |
| 18448017 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | August 2023 | March 2025 | Allow | 19 | 0 | 0 | No | No |
| 18446782 | SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19 | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18447290 | BLOOD BIOMARKER THAT PREDICTS PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION | August 2023 | May 2025 | Allow | 22 | 2 | 0 | No | No |
| 18231460 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES FROM INDIVIDUAL CELLS OR CELL POPULATIONS | August 2023 | October 2024 | Abandon | 14 | 2 | 1 | No | No |
| 18364285 | ILT3-BINDING AGENTS AND METHODS OF USE THEREOF | August 2023 | August 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18363113 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | August 2023 | January 2025 | Allow | 17 | 0 | 0 | No | No |
| 18361731 | SYSTEMS AND METHODS FOR BIOMOLECULE RETENTION | July 2023 | December 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18360073 | TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab | July 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18359633 | Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) | July 2023 | January 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18354144 | SANDWICH ASSAYS IN DROPLETS | July 2023 | February 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18352690 | Application of Retinal Pigment Epithelial Cells as Corneal Endothelial Substitute | July 2023 | January 2025 | Abandon | 19 | 2 | 1 | Yes | No |
| 18221053 | BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS | July 2023 | April 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18350287 | PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN REGULATING GLIOGENESIS | July 2023 | June 2025 | Allow | 23 | 2 | 1 | No | No |
| 18349438 | ANTI-MUC1 ANTIBODY-DRUG CONJUGATE | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18348063 | MULTIPLEX CAPTURE OF GENE AND PROTEIN EXPRESSION FROM A BIOLOGICAL SAMPLE | July 2023 | March 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18347361 | BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 | July 2023 | April 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18340786 | PH20 POLYPEPTIDE VARIANTS WITH A MODIFICATION AT POSITION 324 OF THE PH20 POLYPEPTIDE AND A METHOD OF MAKING THEREOF | June 2023 | August 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18339347 | METHODS OF SCREENING COMPOUNDS | June 2023 | August 2024 | Allow | 13 | 1 | 2 | Yes | No |
| 18336283 | METHODS AND COMPOSITIONS FOR CELL-FREE CLONING | June 2023 | April 2024 | Allow | 10 | 2 | 1 | No | No |
| 18325690 | DIFFERENTIATION OF CORTICAL NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | May 2023 | February 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18200569 | METHOD AND APPARATUS FOR ENCODING CELLULAR SPATIAL POSITION INFORMATION | May 2023 | October 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18313792 | METHODS OF TREATING AL AMYLOIDOSIS | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18143917 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | May 2023 | February 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18312710 | METHODS AND SYSTEMS FOR GENETIC ANALYSIS | May 2023 | January 2024 | Allow | 9 | 2 | 1 | No | No |
| 18311605 | METHODS, COMPOSITIONS, KITS, AND SYSTEMS FOR ENHANCING ANALYTE CAPTURE FOR SPATIAL ANALYSIS | May 2023 | May 2024 | Allow | 12 | 1 | 1 | No | No |
| 18140312 | METHODS, COMPOSITIONS, AND SYSTEMS FOR SPATIAL ANALYSIS OF ANALYTES IN A BIOLOGICAL SAMPLE | April 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18138000 | STABLE LIQUID GONADOTROPIN FORMULATION | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18302421 | SPATIAL ANALYSIS OF EPIGENETIC MODIFICATIONS | April 2023 | June 2024 | Allow | 14 | 1 | 1 | No | No |
| 18300535 | p53 Peptides as Markers in the Diagnosis and Prognosis of Alzheimer's Disease | April 2023 | February 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18300834 | ANTI-CD38 ANTIBODIES AND FORMULATIONS | April 2023 | March 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18299458 | FUSION PROTEINS COMPRISING PROGRANULIN | April 2023 | February 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18298953 | ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERS | April 2023 | September 2024 | Allow | 17 | 2 | 1 | No | No |
| 18298202 | DETECTION AND ANALYSIS OF STRUCTURAL VARIATIONS IN GENOMES | April 2023 | June 2024 | Allow | 14 | 2 | 0 | No | No |
| 18297883 | METHODS FOR DIAGNOSING HUNTINGTON�S DISEASE | April 2023 | April 2025 | Allow | 24 | 2 | 0 | No | No |
| 18190643 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | March 2023 | June 2025 | Abandon | 27 | 4 | 0 | No | No |
| 18190416 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | March 2023 | September 2024 | Allow | 18 | 2 | 0 | No | No |
| 18125075 | METHODS AND KITS USING NUCLEIC ACID ENCODING AND/OR LABEL | March 2023 | July 2024 | Allow | 16 | 1 | 0 | No | No |
| 18185215 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES FROM INDIVIDUAL CELLS OR CELL POPULATIONS | March 2023 | August 2023 | Allow | 5 | 1 | 1 | No | No |
| 18121626 | COMPOSITION AND METHOD FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18182822 | TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES | March 2023 | March 2025 | Allow | 24 | 2 | 0 | No | No |
| 18181943 | METHODS OF DETERMINING A SURGICAL MARGIN AND METHODS OF USE THEREOF | March 2023 | June 2023 | Allow | 3 | 1 | 0 | No | No |
| 18179582 | METHODS AND SYSTEMS FOR GENETIC ANALYSIS | March 2023 | January 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18178764 | METHODS AND SYSTEMS FOR GENETIC ANALYSIS | March 2023 | January 2024 | Allow | 11 | 1 | 1 | No | No |
| 18173116 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | February 2023 | March 2025 | Allow | 24 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1675.
With a 38.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1675 is part of Group 1670 in Technology Center 1600. This art unit has examined 6,205 patent applications in our dataset, with an overall allowance rate of 64.6%. Applications typically reach final disposition in approximately 28 months.
Art Unit 1675's allowance rate of 64.6% places it in the 20% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1675 receive an average of 1.98 office actions before reaching final disposition (in the 65% percentile). The median prosecution time is 28 months (in the 53% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.